ZRANB2

Summary

ZRANB2 (zinc finger RANBP2-type containing 2, HGNC:13058) is a protein-coding gene on chromosome 1p31.1, encoding Zinc finger Ran-binding domain-containing protein 2 (O95218). Splice factor required for alternative splicing of TRA2B/SFRS10 transcripts. It is a selective cancer dependency (DepMap: 32.5% of cell lines).

Enables RNA binding activity. Predicted to be involved in RNA splicing and mRNA processing. Located in nucleoplasm.

Source: NCBI Gene 9406 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 44 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 32.5% of screened cell lines
• MANE Select transcript: NM_203350

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13058
Approved symbol	ZRANB2
Name	zinc finger RANBP2-type containing 2
Location	1p31.1
Locus type	gene with protein product
Status	Approved
Aliases	ZIS, ZIS1, ZIS2
Ensembl gene	ENSG00000132485
Ensembl biotype	protein_coding
OMIM	604347
Entrez	9406

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000254821, ENST00000370920, ENST00000473260, ENST00000477096, ENST00000479947, ENST00000487510, ENST00000611683, ENST00000852037, ENST00000852038, ENST00000852039, ENST00000929967, ENST00000929968, ENST00000929969

RefSeq mRNA: 2 — MANE Select: NM_203350 NM_005455, NM_203350

CCDS: CCDS659, CCDS660

Canonical transcript exons

ENST00000370920 — 10 exons

Exon	Start	End
ENSE00000903865	71072121	71072255
ENSE00000903866	71072472	71072548
ENSE00000903867	71076795	71076877
ENSE00000903868	71078457	71078565
ENSE00000903869	71078656	71078708
ENSE00000995751	71069276	71069362
ENSE00000995752	71070827	71070996
ENSE00001867543	71063291	71065137
ENSE00001954996	71080940	71081035
ENSE00003530659	71066776	71066934

Expression profiles

Bgee: expression breadth ubiquitous, 266 present calls, max score 99.14.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 101.2845 / max 4693.6319, expressed in 1819 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12817	101.2845	1819

Top tissues by expression

266 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	99.14	gold quality
oviduct epithelium	UBERON:0004804	99.08	gold quality
ileal mucosa	UBERON:0000331	99.03	gold quality
calcaneal tendon	UBERON:0003701	98.76	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.65	gold quality
corpus epididymis	UBERON:0004359	98.59	gold quality
caput epididymis	UBERON:0004358	98.48	gold quality
tibialis anterior	UBERON:0001385	98.46	gold quality
adenohypophysis	UBERON:0002196	98.46	gold quality
pituitary gland	UBERON:0000007	98.41	gold quality
tibia	UBERON:0000979	98.38	gold quality
left ventricle myocardium	UBERON:0006566	98.29	gold quality
body of uterus	UBERON:0009853	98.26	gold quality
deltoid	UBERON:0001476	98.23	gold quality
cauda epididymis	UBERON:0004360	98.12	gold quality
left ovary	UBERON:0002119	98.09	gold quality
upper arm skin	UBERON:0004263	98.08	gold quality
sural nerve	UBERON:0015488	98.07	gold quality
right ovary	UBERON:0002118	98.06	gold quality
peripheral nervous system	UBERON:0000010	98.00	gold quality
nerve	UBERON:0001021	98.00	gold quality
tibial nerve	UBERON:0001323	98.00	gold quality
seminal vesicle	UBERON:0000998	97.98	gold quality
right uterine tube	UBERON:0001302	97.98	gold quality
ovary	UBERON:0000992	97.95	gold quality
mucosa of stomach	UBERON:0001199	97.94	gold quality
germinal epithelium of ovary	UBERON:0001304	97.91	gold quality
rectum	UBERON:0001052	97.80	gold quality
pancreatic ductal cell	CL:0002079	97.74	gold quality
fallopian tube	UBERON:0003889	97.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6386	no	554.39
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

93 targeting ZRANB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 32.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 4)

• sites responsible for MRNA binding have been characterized. (PMID:12657633)
• Crystallization of a ZRANB2-RNA complex (PMID:19052380)
• ZRANB2 is part of the supraspliceosome and causes differential splicing of numerous primary transcripts, some of which might have a role in cancer. (PMID:23666063)
• These data identify Aletrnative splicing programs controlled by ZRANB2 and SYF2 and converging on ECT2, that participate to breast cancer cell resistance to doxorubicin. (PMID:31943118)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zranb2	ENSDARG00000044332
mus_musculus	Zranb2	ENSMUSG00000028180
rattus_norvegicus	Zranb2	ENSRNOG00000009990
drosophila_melanogaster	CG3732	FBGN0034750
caenorhabditis_elegans		WBGENE00021295

Protein

Protein identifiers

Zinc finger Ran-binding domain-containing protein 2 — O95218 (reviewed: O95218)

Alternative names: Zinc finger protein 265, Zinc finger, splicing

All UniProt accessions (1): O95218

UniProt curated annotations — full annotation on UniProt →

Function. Splice factor required for alternative splicing of TRA2B/SFRS10 transcripts. Binds to ssRNA containing the consensus sequence 5’-AGGUAA-3’. May interfere with constitutive 5’-splice site selection.

Subunit / interactions. Interacts with the C-terminal half of SNRNP70, the Arg/Ser-rich domain of AKAP17A as well as with U2AF1 and CLK1.

Subcellular location. Nucleus.

Post-translational modifications. Isoform 2 is phosphorylated on Ser-310 upon DNA damage, probably by ATM or ATR.

Domain organisation. The RanBP2-type zinc fingers mediate binding to RNA.

Similarity. Belongs to the ZRANB2 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O95218-1	1, ZIS-1	yes
O95218-2	2, ZIS-2

RefSeq proteins (2): NP_005446, NP_976225* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001876	Znf_RanBP2	Domain
IPR017337	ZRANB2	Family
IPR036443	Znf_RanBP2_sf	Homologous_superfamily

Pfam: PF00641

UniProt features (34 total): modified residue 13, compositionally biased region 7, strand 3, turn 3, zinc finger region 2, region of interest 2, chain 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
3G9Y	X-RAY DIFFRACTION	1.4
1N0Z	SOLUTION NMR
2K1P	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95218-F1	56.70	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (13): 9, 18, 54, 92, 120, 153, 181, 188, 193, 303, 305, 307, 310

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 118 (showing top): FISCHER_G1_S_CELL_CYCLE, AAGCCAT_MIR135A_MIR135B, CAFFAREL_RESPONSE_TO_THC_UP, GTGCCTT_MIR506, CATTTCA_MIR203, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_RNA_SPLICING, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ELK1_01, ZHANG_BREAST_CANCER_PROGENITORS_UP, TGCCTTA_MIR124A, CAFFAREL_RESPONSE_TO_THC_24HR_5_DN, STAT1_02, SCGGAAGY_ELK1_02

GO Biological Process (3): mRNA processing (GO:0006397), RNA splicing (GO:0008380), RNA processing (GO:0006396)

GO Molecular Function (5): lipopolysaccharide binding (GO:0001530), RNA binding (GO:0003723), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleoplasm (GO:0005654), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
mRNA metabolic process	1
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
lipid binding	1
carbohydrate derivative binding	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
nuclear lumen	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1492 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZRANB2	SNRNP70	P08621	756
ZRANB2	RANBP2	P49792	601
ZRANB2	U2AF1	Q01081	577
ZRANB2	TDG	Q13569	552
ZRANB2	RBMX	P38159	543
ZRANB2	AGGF1	Q8N302	520
ZRANB2	MKRN1	Q9UHC7	501
ZRANB2	SYF2	O95926	430
ZRANB2	OR4C6	Q8NH72	405
ZRANB2	ASZ1	Q8WWH4	403
ZRANB2	TRA2B	P62995	401
ZRANB2	C1QBP	Q07021	395
ZRANB2	RBM5	P52756	389
ZRANB2	TRA2A	Q13595	375
ZRANB2	NPM1	P06748	366

IntAct

83 interactions, top by confidence:

A	B	Type	Score
PIP4K2A	AHCYL1	psi-mi:“MI:0914”(association)	0.730
AKAP17A	ZRANB2	psi-mi:“MI:0915”(physical association)	0.650
AKAP17A	ZRANB2	psi-mi:“MI:0403”(colocalization)	0.650
ZRANB2	ARRB1	psi-mi:“MI:0915”(physical association)	0.640
LUC7L2	ZRANB2	psi-mi:“MI:0914”(association)	0.640
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
ZRANB2	PIP4K2A	psi-mi:“MI:0914”(association)	0.610
ZRANB2	LRRK2	psi-mi:“MI:0407”(direct interaction)	0.590
MAPT	KIF2A	psi-mi:“MI:0914”(association)	0.530
EPB41L2	AP3B1	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
LRRK2	DFFA	psi-mi:“MI:0914”(association)	0.530
EPB41L3	AP3B1	psi-mi:“MI:0914”(association)	0.530
ZMYM4	ILVBL	psi-mi:“MI:0914”(association)	0.530
DYNC2I1	ZRANB2	psi-mi:“MI:0914”(association)	0.510
ARRB2	ZRANB2	psi-mi:“MI:0915”(physical association)	0.500
U2AF2	U2SURP	psi-mi:“MI:0914”(association)	0.480
ZRANB2	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
ZRANB2	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
KIF20A	ZRANB2	psi-mi:“MI:0915”(physical association)	0.370
DDX41	DDX39A	psi-mi:“MI:0914”(association)	0.350
HIF1AN	CNOT1	psi-mi:“MI:0914”(association)	0.350
ARRB1		psi-mi:“MI:0914”(association)	0.350
ARRB2		psi-mi:“MI:0914”(association)	0.350
METTL3	TUBAL3	psi-mi:“MI:0914”(association)	0.350

BioGRID (255): ZRANB2 (Affinity Capture-MS), ZRANB2 (Affinity Capture-MS), TOP1 (Affinity Capture-MS), PRPF4B (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L (Affinity Capture-MS), KPNA5 (Affinity Capture-MS), RPL26L1 (Affinity Capture-MS), RSBN1L (Affinity Capture-MS), RSBN1 (Affinity Capture-MS), LUC7L3 (Affinity Capture-MS), VANGL1 (Affinity Capture-MS), PIP4K2C (Affinity Capture-MS), PIP4K2B (Affinity Capture-MS), PIP4K2A (Affinity Capture-MS)

ESM2 similar proteins: A0A1S3XQD6, A0A1S4AX27, A1A5I1, A2AR02, A6QLS2, B0BN49, O35986, O55035, O95218, P30189, P30414, P30415, Q19QU3, Q27450, Q28EE8, Q2HJC9, Q3B7G7, Q3KPW4, Q4P4G8, Q4V8I5, Q4V9W2, Q502P0, Q505I5, Q5BKY9, Q5F4A9, Q5R580, Q5R8J6, Q5RJP9, Q5VTL8, Q5XHJ5, Q5ZLM8, Q5ZLX5, Q66PJ3, Q6AXY7, Q6C1V6, Q6NQD9, Q6P7Y3, Q6ZUT1, Q7L4I2, Q80SY5

Diamond homologs: O35986, O95218, Q19QU3, Q5R580, Q5ZLX5, Q92804, Q94KD0, Q9AST1, Q9R020, Q8GZ43, O43120, P35637, P56959, Q01844, Q03251, Q05966, Q27294, Q28009, Q44560, Q61545, Q6C747, Q9LIS2, Q9SVM8, Q9WX37, Q9WX39, A0A0D1DZT6, O43719, P11940, P53830, P61286, Q5R8F7, Q5RB63, Q8BGC0, Q9H361, O75526, P49311, Q29RT0, Q499V6, Q4R813, Q56JZ7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 88 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA Splicing - Major Pathway	12	10.2×	8e-07
Dengue Virus-Host Interactions	9	6.4×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
spliceosomal complex assembly	6	47.5×	1e-06
mRNA splicing, via spliceosome	11	13.3×	5e-07
negative regulation of canonical NF-kappaB signal transduction	5	11.3×	8e-03
RNA splicing	9	10.4×	3e-05
mRNA processing	10	10.4×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1513 predictions. Top by Δscore:

Variant	Effect	Δscore
1:71066935:C:CC	acceptor_gain	1.0000
1:71066939:A:C	acceptor_gain	1.0000
1:71066940:T:C	acceptor_gain	1.0000
1:71066940:T:TC	acceptor_gain	1.0000
1:71066943:A:AC	acceptor_gain	1.0000
1:71066943:A:C	acceptor_gain	1.0000
1:71066944:T:C	acceptor_gain	1.0000
1:71066944:T:TC	acceptor_gain	1.0000
1:71066957:C:CT	acceptor_gain	1.0000
1:71066962:A:C	acceptor_gain	1.0000
1:71066966:C:CT	acceptor_gain	1.0000
1:71066967:A:C	acceptor_gain	1.0000
1:71066968:T:C	acceptor_gain	1.0000
1:71066968:T:TC	acceptor_gain	1.0000
1:71070828:TGG:T	donor_gain	1.0000
1:71070993:CATC:C	acceptor_gain	1.0000
1:71070997:C:CC	acceptor_gain	1.0000
1:71071884:T:TA	donor_gain	1.0000
1:71071887:T:TA	donor_gain	1.0000
1:71072117:TCA:T	donor_loss	1.0000
1:71072118:CA:C	donor_loss	1.0000
1:71072119:A:C	donor_loss	1.0000
1:71072122:T:TA	donor_gain	1.0000
1:71072125:T:C	donor_gain	1.0000
1:71072129:A:C	donor_gain	1.0000
1:71072130:C:CC	donor_gain	1.0000
1:71072133:A:AC	donor_gain	1.0000
1:71072152:T:TA	donor_gain	1.0000
1:71072157:AT:A	donor_gain	1.0000
1:71072158:T:TA	donor_gain	1.0000

AlphaMissense

2109 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:71072248:C:G	R129P	1.000
1:71072249:G:T	R129S	1.000
1:71072251:C:A	G128V	1.000
1:71072251:C:T	G128E	1.000
1:71072252:C:G	G128R	1.000
1:71072252:C:T	G128R	1.000
1:71072253:A:C	F127L	1.000
1:71072253:A:T	F127L	1.000
1:71072254:A:C	F127C	1.000
1:71072254:A:G	F127S	1.000
1:71072255:A:C	F127V	1.000
1:71072255:A:G	F127L	1.000
1:71072255:A:T	F127I	1.000
1:71072475:A:C	D125E	1.000
1:71072475:A:T	D125E	1.000
1:71072476:T:A	D125V	1.000
1:71072476:T:C	D125G	1.000
1:71072476:T:G	D125A	1.000
1:71072477:C:A	D125Y	1.000
1:71072477:C:G	D125H	1.000
1:71072510:A:G	Y114H	1.000
1:71072523:T:A	R109S	1.000
1:71072523:T:G	R109S	1.000
1:71072524:C:G	R109T	1.000
1:71072527:T:A	E108V	1.000
1:71072528:C:T	E108K	1.000
1:71072532:A:C	F106L	1.000
1:71072532:A:T	F106L	1.000
1:71072533:A:C	F106C	1.000
1:71072533:A:G	F106S	1.000

dbSNP variants (sampled 300 via entrez): RS1000016859 (1:71079997 TA>T,TAA), RS1000165348 (1:71075766 C>G), RS1000244825 (1:71075626 A>G,T), RS1000296728 (1:71081278 C>G,T), RS1000328559 (1:71074560 T>C), RS1000564587 (1:71077108 G>A,C), RS1000628404 (1:71076504 C>G), RS1000723555 (1:71082135 G>A,C), RS1000935600 (1:71072933 C>T), RS1001141566 (1:71070460 C>G), RS1001265354 (1:71068684 A>T), RS1001271061 (1:71081346 C>T), RS1001368086 (1:71072603 C>T), RS1001413989 (1:71064712 T>A), RS1001514503 (1:71063750 A>T)

Disease associations

OMIM: gene MIM:604347 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002701_19	Verbal declarative memory	2.000000e-06
GCST009267_17	Dental caries (decayed, missing and filled teeth)	3.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance
EFO:0006805	word list delayed recall measurement
EFO:0006806	paragraph delayed recall measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725053 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.26	Kd	55	nM	MOLIBRESIB
7.05	IC50	90	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179131: Binding affinity against ZRANB2 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0550	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, affects splicing	3
bisphenol A	decreases expression	2
perfluorooctane sulfonic acid	decreases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	increases expression	1
trichostatin A	affects cotreatment, decreases expression	1
arsenite	increases abundance, increases expression, affects splicing	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
coumarin	decreases phosphorylation	1
cupric oxide	increases expression	1
beta-methylcholine	affects expression	1
fenpyroximate	increases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	increases expression	1
pyrimidifen	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Antimycin A	increases expression	1
Arsenic	increases abundance, increases expression, affects cotreatment	1
Caffeine	affects phosphorylation	1
Coal	increases abundance, decreases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697185	Binding	Inhibition of ZRANB2 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.